US Stock MarketDetailed Quotes
MESO Mesoblast
- 11.030
- +0.920+9.10%
Close Nov 25 16:00 ET
- 11.030
- 0.0000.00%
Post 20:01 ET
1.26BMarket Cap-12379P/E (TTM)
11.400High10.630Low228.75KVolume10.750Open10.110Pre Close2.51MTurnover0.27%Turnover RatioLossP/E (Static)114.18MShares12.17952wk High2.62P/B936.96MFloat Cap1.61052wk Low--Dividend TTM84.95MShs Float106.340Historical High--Div YieldTTM7.62%Amplitude1.610Historical Low10.992Avg Price1Lot Size
Mesoblast Stock Forum
Sign in to post a comment
$Mesoblast (MESO.US)$ …got approval from FDA??
1
$Mesoblast (MESO.US)$ How low will it go?
1
1
$Mesoblast (MESO.US)$ … today back to 10
1
7
$Mesoblast (MESO.US)$ .. will drop then rocket by end of this year
1
2
$Mesoblast (MESO.US)$
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch | MESO Stock News
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch | MESO Stock News
1
1
$Mesoblast (MESO.US)$ .. if below to 5.. nice to buy!!!
2
4
$Mesoblast (MESO.US)$ Mesoblast (MESO) has released an update. Mesoblast Limited has resubmitted a Biologics License Application (BLA) to the FDA for Ryoncil®, aiming to treat children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD). The resubmission, buoyed by promising Phase 3 study results demonstrating significant survival benefits, could meet an urgent need for effective treatment in this patient group, as current survival outcomes are poor and no FDA-approved treatm...
2
8
$Mesoblast (MESO.US)$ which is developing off-the-shelf cellular medicines for life-threatening inflammatory conditions, is planning to file a Biologics License Application for Ryoncil with the FDA next week.
2
2
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Aariya : may be almost there or already done but not yet published